Replimune/$REPL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Replimune
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Ticker
$REPL
Sector
Primary listing
Employees
465
Headquarters
Website
Replimune Metrics
BasicAdvanced
$923m
-
-$3.38
0.87
-
Price and volume
Market cap
$923m
Beta
0.87
52-week high
$13.24
52-week low
$1.50
Average daily volume
5.4m
Financial strength
Current ratio
4.794
Quick ratio
4.646
Long term debt to equity
64.724
Total debt to equity
67.156
Interest coverage (TTM)
-35.93%
Profitability
EBITDA (TTM)
-312.555
Effective tax rate (TTM)
0.18%
Management effectiveness
Return on assets (TTM)
-45.03%
Return on equity (TTM)
-107.88%
Valuation
Price to book
5.47
Price to tangible book (TTM)
5.47
Price to free cash flow (TTM)
-3.584
Free cash flow yield (TTM)
-27.90%
Free cash flow per share (TTM)
-3.066
Growth
Earnings per share change (TTM)
10.21%
3-year earnings per share growth (CAGR)
4.16%
What the Analysts think about Replimune
Analyst ratings (Buy, Hold, Sell) for Replimune stock.
Replimune Financial Performance
Revenues and expenses
Replimune Earnings Performance
Company profitability
Replimune News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.